Top Page
Actinogen Medical
(Sydney:ACW)
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Actinogen Medical Business Overview & Revenue Model
Actinogen Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.29M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -15.01M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -14.73M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 24.48M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 16.50M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 3.26M | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 6.15M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 18.34M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -7.59M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -7.56M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.02K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 14.65M | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Actinogen Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$92.44M | 13.48 | 27.24% | 2.81% | 0.65% | -9.90% | |
55 Neutral | AU$85.06M | -1.35 | -100.67% | ― | 1114.27% | 85.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$89.38M | -9.01 | -49.72% | ― | ― | 10.78% | |
47 Neutral | AU$159.59M | -9.80 | -75.99% | ― | ― | 10.91% | |
44 Neutral | AU$105.70M | -12.65 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% |
Actinogen Medical Corporate Events
Actinogen Medical Limited has applied to the ASX for quotation of 43,392 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly expands the company’s share capital base, reflecting ongoing issuance under existing equity arrangements but without indicating any major change in its operational strategy or capital structure.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has dispatched four senior executives to San Francisco to meet investors, analysts and potential partners at the Sachs Neuroscience Innovation Forum and events around the J.P. Morgan Healthcare Conference, aiming to raise the company’s profile among key neuroscience-focused stakeholders. The meetings centre on the company’s Xanamem Alzheimer’s program, highlighting multiple supportive clinical trials and the advanced XanaMIA Phase 2b/3 study, which has completed recruitment and is on track to deliver an interim analysis in late January 2026 and final topline results in November 2026, a timeline that could be pivotal for Actinogen’s clinical and commercial positioning if the data are positive.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has applied to the ASX for quotation of 4,695,960 new fully paid ordinary shares, to be issued on 8 January 2026 under the code ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s listed share base and may provide incremental funding flexibility and liquidity for shareholders as Actinogen progresses its development activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 82,093 new fully paid ordinary shares, to be issued on 2 January 2026 under the ticker ACW. The modest increase in quoted securities reflects the conversion or exercise of existing options or other convertible instruments, slightly expanding the company’s share base and providing incremental capital or aligning incentives for stakeholders, without indicating any major strategic shift in its operations.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 4,000,000 new ordinary fully paid shares, which are scheduled to be issued and commence trading on 23 December 2025 under the ticker ACW. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, modestly expand the company’s share base and may provide incremental capital and liquidity, with implications for existing shareholders through potential dilution and for the company’s financial flexibility as it advances its business activities.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has applied to the ASX for quotation of 218,449 new ordinary fully paid shares, to be listed under its existing ticker ACW. The additional securities, issued on 19 December 2025 following the exercise or conversion of existing instruments, will modestly expand the company’s free float and may incrementally enhance liquidity for shareholders without indicating any broader strategic shift in operations.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical has completed participant enrollment for its XanaMIA phase 2b/3 clinical trial, aimed at evaluating its novel Alzheimer’s treatment, Xanamem. The trial enrolled 246 participants, exceeding the initial target, which enhances its statistical power. Data will be assessed through an interim analysis in early 2026, with topline results anticipated by November 2026. This milestone underscores the potential of Xanamem as a groundbreaking, once-daily oral therapy designed to control brain cortisol, with implications for Alzheimer’s patients and the broader neurotherapeutic market.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 101,001 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 12, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operations and positioning within the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 251,050 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 5, 2025. This move marks a significant step for the company, potentially enhancing its market presence and providing additional capital for its operations, which could positively impact its stakeholders.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the quotation of 1,078,721 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 1, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support ongoing research and development activities, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
Actinogen Medical Limited has announced the issuance of 2,769,826 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code ACW. This move is part of the company’s strategic efforts to enhance its capital structure and support its ongoing research and development activities, potentially strengthening its position in the biotechnology sector and providing new opportunities for stakeholders.
Actinogen Medical announced the results of its Annual General Meeting, where all resolutions, including the approval of increased placement capacity, were carried. The company is advancing its clinical trials for Xanamem, a promising treatment for Alzheimer’s and depression, with significant progress in ongoing trials. The XanaMIA Phase 2b/3 trial for Alzheimer’s is set to be fully enrolled by the end of 2025, with initial results expected in early 2026. Actinogen’s efforts in controlling brain cortisol levels through Xanamem have shown promising safety and efficacy in clinical trials, reinforcing its potential impact on the treatment of neurological diseases.
Actinogen Medical announced that its CEO and CFO will present at the Bell Potter Healthcare Conference 2025, highlighting their lead compound, Xanamem, which targets brain cortisol to slow Alzheimer’s progression and treat depression. The company is conducting multiple clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, with promising results showing significant benefits on depressive symptoms and cognitive function. These developments could strengthen Actinogen’s position in the biotechnology industry and offer new hope for patients with debilitating neurological conditions.
Actinogen Medical held its 2025 Annual General Meeting in Sydney, where the Chair and CEO presented updates on their clinical trials and strategic direction. The company is advancing its XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with full enrollment expected by the end of 2025 and initial results in early 2026. The XanaCIDD trial for depression showed significant benefits, reinforcing the potential of Xanamem in treating cognitive and depressive symptoms. These developments position Actinogen as a promising player in the biotechnology industry, with potential implications for stakeholders in terms of future treatment options and market growth.
Actinogen Medical announced that the independent Data Monitoring Committee has recommended the continuation of the XanaMIA phase 2b/3 trial for Alzheimer’s without any amendments after reviewing safety data from 153 participants. This decision marks a positive step for the company’s development of Xanamem, a promising therapy targeting elevated cortisol levels in the brain, which is linked to Alzheimer’s progression and depressive symptoms. The trial is expected to be fully enrolled by the end of 2025, with interim results anticipated in early 2026, potentially impacting the company’s position in the neurological treatment market.
Actinogen Medical announced its participation at the BIO-Europe 2025 conference in Vienna, where its executives will engage with international investors and potential biopharma partners to discuss their late-stage clinical trial program for Alzheimer’s disease. The company is conducting a pivotal phase 2b/3 trial for Alzheimer’s, with interim results expected early next year and final results in late 2026. This conference provides an opportunity to explore regional collaborations to accelerate the development of Xanamem, which has shown promising results in controlling elevated cortisol levels in the brain, a factor linked to Alzheimer’s progression and depressive symptoms.
Actinogen Medical announced a live webinar to discuss recent progress and upcoming milestones, highlighting the development of their lead compound, Xanamem, for Alzheimer’s Disease and Depression. The company is conducting clinical trials in Australia and the US, with promising results from previous studies showing significant benefits in depression symptoms and cognitive function. The ongoing trials aim to further validate Xanamem’s efficacy and safety, potentially impacting the treatment landscape for these debilitating conditions.
Actinogen Medical announced a live webinar scheduled for October 28, 2025, where CEO Dr. Steven Gourlay and other leaders will discuss the company’s recent progress and upcoming milestones. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant developments expected in 2026. This announcement highlights Actinogen’s commitment to addressing unmet medical needs in neurological and neuropsychiatric diseases, potentially impacting its market position and offering hope for stakeholders seeking new treatments.
Actinogen Medical has announced accelerated enrolment in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim analysis scheduled for January 2026 and final results expected in mid-Q4 2026. The company also reported a successful meeting with the FDA, paving the way for a streamlined path to marketing approval and enhancing its potential for partnerships. Additionally, Actinogen has launched an Investor Hub to engage shareholders and successfully completed a pharmacokinetic trial confirming the efficacy of Xanamem’s commercial formulation. These developments signify significant progress in Actinogen’s clinical and commercial strategies, potentially strengthening its position in the Alzheimer’s treatment market.